These peptides are inhibitors of a protein called myostatin. Myostatin is secreted by muscle cells and acts to essentially block the development of new muscle fibers and, thus, the development of lean muscle mass. In fact, individuals who have mutations in the gene coding for this protein have significantly more muscle mass and enhanced strength. The administration of follastatin peptides can generate enhanced muscle mass and strength, and has been found especially useful in patients suffering from muscle-wasting diseases or who have difficulty gaining muscle.
Nevertheless, the hypothesis that AOD9604 does not activate the hGH/IGF-1 axis had to be tested in humans. The studies presented here confirm the in-vitro results. In these studies no clinically relevant changes of IGF-1 levels were observed and no differences to the placebo treatment were found. Together with the lack of any other symptoms associated with known IGF-1 mediated effects, such as sodium retention, tissue oedema, hypertension, or impaired glucose tolerance, the results demonstrate that AOD9604 does not activate the hGH/IGF-1 pathway and therefore has no growth promoting effect.
The human growth hormone (hGH) is a 191-amino acid long, single-chain polypeptide secreted by the pituitary gland under the regulation of the hypothalamus. It regulates a variety of biological processes in various tissues. When binding to the hGH-receptor it activates one of various signaling cascades, depending on the tissue. In the liver hGH induces the secretion of Insulin-Like Growth Factor-1 (IGF-1). IGF-1 can stimulate growth in almost every tissue in the body, including skeletal muscle, cartilage, bone, liver, kidney, nerves etc. [1].
A large difference between steroid hormones and peptide hormones is that some steroid hormones exhibit oral activity, in that they can be active after they are taken by mouth. However, many peptide hormones are digested in the same way as proteins. They are broken down into amino acids in the digestive system, which means they no longer have the bioactivity of their parent compound. Consequently, they may require administration through injections.
The test substance was either administered intravenously (studies METAOD001 and METAOD002) or as a capsule/tablet. The hexadecapeptide AOD9604 was produced under cGMP conditions by PolyPeptide Laboratories (Torrance, CA, USA). For studies 1 and 2, the product was supplied in a lyophilized form and reconstituted before usage with the designated volume of sterile water for intravenous injection. The capsules/tablets were manufactured using a common excipient mix (Capsules: Mannitol, PEG3350 (in studies METAOD003, METAOD004 and METAOD005)); or Tablets: L-Arginine Free Base, Microcrystalline Cellulose, Fumed silica, Magnesium Stearate (in study METAOD006)).

I'm using 100mcg 6am-12pm-6pm(3xday) HGH Fragment 176-191 and the last shot around 6pm taking 100mcg of GHRP-6 from SouthernResearchCo, I gotta brag on their quality and value there's no others on the same level (IMO)! I dropped 10-15lbs as soon as I started too! NO catabolic or any adverse effects. Well, I did get head aches and super shits when I first began but by wk2 I notice nothing and feel so great! My tummy looks so much better too, my wifes all jealous as hell n gets mad saying she wont compliment it cuz I use drugs to attain leanness lol Fk it
People who are serious about losing weight or improving physical performance may choose to use some of the controversial peptides. They are generally sold for research purposes, but many injectable forms of peptides have been used by athletes to increase the production of their body’s HGH to achieve increased lean body mass, decreased body fat, and improved recovery time after workouts. Peptides used for these purposes include:

The banned "peptide" believed to have been injected into numerous Australian professional athletes can be bought in under 30 seconds online. GHRP-6, the growth hormone-releasing peptide that features in the Australian Crime Commission's report into organised crime and drugs in sport released this morning, was identified -- alongside other so-called performance and image enhancing drugs (PIEDs) -- as a dubious supplement threatening to cast a pall over the country's professional codes. Although unproven, GHRP-6 purportedly helps the body repair damaged tissue and can stimulate human growth hormones to improve athletic performance. It can be used in conjunction with anabolic steroids to promote muscle gain. Peptides are classified as a prohibited substance on the World Anti-Doping Agency prohibited list and were banned for use both in and out of competition in 2008. The ACC report said most peptides are also:


Acromegaly is characterized by an excessive amount of articular cartilage in joints caused by excess GH secretion [25]. The tremendously thick articular cartilage in acromegaly can be explained by the local production of IGF-1 in cartilage cells through GH receptors [9,18]. Long-term treatment with GH might induce hypertrophy of the cartilage and changes in the joint geometry because of altered subchondral bone structures. Long-term treatment with GH by local injections may also be associated with various risks, including glucose intolerance, insulin resistance, diabetes, cancer, edema, and hypertension [26–29]. AOD9604 is not an agonist with a high affinity to the GH receptor and does not stimulate the production of IGF-1. Therefore, AOD9604 may be safer than human recombinant GH for the long-term treatment of OA.

Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) used in the management of mild to moderate pain and inflammation in conditions such as dysmenorrhoea, headache including migraine, post-operative pain, dental pain, musculoskeletal and joint disorders such as ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis including juvenile idiopathic arthritis, peri-articular disorders such as bursitis and tenosynovitis, and soft tissue disorders such as sprains and strains. It is also used to reduce fever.
As simple and basic as it is, eating less calories is much harder in practice than it sounds. Ask anyone who has ever gone on a diet before! Everyone knows if you want to lose weight, you need to eat less. It’s the first step of any legitimate diet and fitness program, but how much less, and what to eat remains a mystery to many dieters. Or, the results don’t come quickly enough and the dieter gives up before real results are experienced.
Fenphedra could have easily been our #1 rated diet pill for women if not for its safety concerns. There have been rumors Fenphedra contains phentermine and prescription-strength pain relievers. Any rumors of such claims are completely false, but Fenphedra does contain phenylethylamine. Often referred to as the “Love Drug,” phenylethylamine is extracted from cocoa and responsible for the “chocolate high” sensation. Fenphedra also contains Green Coffee Bean, Chromax and Dicaffeine Malate, which dramatically burn fat, suppress appetite, and increase energy. Finding bottles of Fenphedra in the U.S. can be difficult because rumors are flourishing that it may be taken off the market like banned diet pills for women. Fenphedra retails for $130 per bottle and comes with a 100% money-back guarantee. The cheapest place to buy online occasionally has bottles available for as low as $69.95. Read More
recently studies found that in the process of destroying the fat cells, it shook stem cells which are inside the fat cells giving rise to new found REGENERATIVE POWERS of AOD. It works well at regenerating ligaments after significant damage and muscle repair, by increasing cartilage and collagen production in your joints. It has also been seen to improve bone density which can have positive effects on osteoporosis.
Resting plasma concentrations of mature BNP and Nt‐proBNP were 14±3 pg/mL and 42±9 pg/mL before gastric bypass surgery and increased to 32±5 pg/mL and 107±20 pg/mL (increased by 50% and 31%), respectively (P=0.0009 and 0.0001) after the surgery. Circulating BNP and Nt‐proBNP concentrations during saline infusion were also higher after surgery compared with before surgery (Figures 2A and 2B; P<0.0001). The saline infusion itself was not associated with an increase in BNP or Nt‐proBNP levels at either visit (P=0.65 and 0.60, respectively).
When you are just getting started with Ipamorelin, it is advised to use only one supplement daily at the same time each day. It is also advised to begin on the lower end, typically an eight-week cycle, and at a maximum twelve-week cycle. Doing this not only guarantees the desired results when using Ipamorelin, it is also going to ensure you get the most out of the supplement. When using this dosage cycle you will:
HUMAN GH (hGH) has profound lipolytic/antilipogenic actions in vivo, which result in decreased fat mass, increased lean mass, and weight loss (1–3). Studies in vitro and in vivo have indicated that this response is mediated in part by an increase inβ -adrenoceptor coupling efficiency (4), a reduction in Gi expression (5), increased activity of hormone sensitive lipase (6), and an inhibitory effect on the action of insulin (7). We have synthesized a fragment of hGH (AOD9604) that contains a lipolytic domain that may be responsible for the lipolytic action of hGH. The parent molecule, AOD9401, induces lipolysis and antilipogenesis and fat oxidation in adipose tissue in vitro (8, 9). In vivo, AOD9401 induces weight loss without affecting food intake as well as increasing lipolytic sensitivity and increasing fat oxidation with no adverse effects on insulin sensitivity (8, 10).
After the commencement of the active treatment 88.9% of subjects experienced at least one AE, whereby the distribution was similar in the 5 AOD9604 groups and the placebo group. There was a higher incidence (48.4%) of nervous system disorders (mainly headache, 42.6%), gastrointestinal disorders (30.4%, mainly diarrhea unspecified, 9.0%) and infections and infestations (45.3%), than seen before the commencement of active treatment. The distribution of the intensity of AEs was similar across all treatment groups. The percentage of AEs that deemed to be possibly or probably related to the study medication was similar across all treatment groups, including placebo.
This particular peptide offers therapeutic benefits similar to those of hGH. CJC 1295 is a growth hormone releasing hormone (GHRH) analogue. In other words, it is a molecule that serves the same purpose as does GHRH—the hormone that stimulates the anterior pituitary to release hGH. However, unlike GHRH, which has a half-life of only minutes after IV administration, CJC 1295 is able to remain active in the body for extended periods due to its ability to bind to a protein in the blood known as albumin and avoid degradation by various enzymes. CJC 1295 increases an important growth factor, IGF-1, in addition to hGH, leading to fat loss, lean muscle growth, and enhanced sleep.
The process to get a cream doesn't happen overnight. Explains Smeath: "A patient will complete a comprehensive medical questionnaire, which is sent to one of our prescribing doctors. [They] review all medical notes, make contact with the patient and once approved, send a prescription to one of two TGA-approved compounding pharmacies in Australia who ship [the peptides] directly."
Natriuretic peptide measurements were tested for normality and were logarithmically transformed for analysis. We used paired t tests to examine the change in BMI, blood pressure, and natriuretic peptides before and after surgery. Mixed effect models using all non‐missing data from 18 study subjects were used to assess the effects of surgery and intravenous saline and their interaction on plasma Nt‐proANP, Nt‐proBNP, and mature ANP and BNP levels, as well as echocardiographic measures. To account for repeated measures for each subject, a spatial power structure for ANP. Nt‐proANP, BNP, and Nt‐proBNP, and a completely general (unstructured) covariance matrix for echocardiographic outcomes were used. None of the interactions terms were significant and P values reported are based on models without interaction. A secondary analysis after covariate adjustment for age, sex, and blood pressure was also performed. All analyses were conducted using SAS (Cary, NC). A two‐sided P<0.05 was considered statistically significant for the primary outcome.
The medicines delegate referred the proposal to upschedule paracetamol/ibuprofen from Schedule 2 to Schedule 3 to the Advisory Committee on Medicines Scheduling (ACMS) in early 2011. The proposal was submitted by the Advisory Committee on Non-Prescription Medicines (ACNM) as they were currently assessing a product in which the sponsor did not satisfactorily establish the efficacy and safety of the product and that public health concerns raised during the assessment of the product could be addressed by access to a pharmacist. AFT Pharmaceuticals had submitted a product application with the TGA at the time of this item being considered by the delegate and ACMS.

The rabbits were clinically observed daily at 14:00. The rabbits were placed on a 2-m2 ground area, and gait was individually assessed by direct observation for 20 minutes. The knee and ankle of the intact rabbit limb showed typical flexion and extension cycle during hopping. Lameness was defined as the inability to bear weight and the loss of typical flexion and extension cycle of the affected limb during hopping compared with that of the unaffected limb. The severity of lameness was not quantified. The time taken to return to normal ambulation without lameness of the affected limb was recorded for each group. The lameness period was checked by three independent physiatrists who did not have knowledge of the experimental groups.


•If injecting just a GHRP or GHRH product on their own, avoid eating/drinking anything high in fat for 3 hours before your injection and anything high in carbohydrates for 2 hours before (i.e. always do your injection on an empty stomach), otherwise the amount of GH release they cause may be significantly blunted leading to poor results. •If injecting both a GHRP and GHRH together (e.g. 100mcg of both GHRP-6 and Modified GRF 1-29) studies have proven that their ability to release GH returns to full-strength as little as 1 hour (60 minutes) post-meal. This gives users greater flexibility with their meal timings, especially since consuming sufficient calories is so critical to building muscle. •Whether injecting GH peptides alone or along with others, always wait at least 20 minutes after your injection before consuming anything. Once at least 20 minutes has passed, consume a food/beverage high in protein and/or carbohydrates to stimulate an insulin spike (if you inject in the morning and around your workout, this meal/shake should be high protein and high carbohydrates, if you inject at night this consumption should be protein only as protein is sufficient enough to spike insulin, but without the negative impact on fat gain which carbohydrates can contribute to).
Other peptides amplify the body’s response to its own testosterone site-specifically within muscle and bone only. Steroids, on the other hand, produce their highly desired anabolic effects by acting on these receptors, but also come coupled with the less-sought-after side effects of acne, oily skin, hair loss, aggression, breast enlargement and testicular shrinkage. It is for this reason, these amino acid chains are serving as an increasingly popular alternative to steroids amongst aesthetic gym goers, providing many of the anabolic effects without the unwanted side effect profile.
Ipamorelin is a man-made peptide that is part of the growth hormone family. Rated as one of the safest in the peptide industry, it has strong growth hormone releasing properties. From this, it is a huge winner with athletes and bodybuilders. This is because it builds muscle and keeps weight down quickly. It works by sending signals to the pituitary gland at the base of the brain and adjusts and controls various body functions through the endocrine system. It binds certain receptors inside cells. This allows cells to respond and change, encouraging growth and regulation of hormones. Ipamorelin can help with:

I'm using 100mcg 6am-12pm-6pm(3xday) HGH Fragment 176-191 and the last shot around 6pm taking 100mcg of GHRP-6 from SouthernResearchCo, I gotta brag on their quality and value there's no others on the same level (IMO)! I dropped 10-15lbs as soon as I started too! NO catabolic or any adverse effects. Well, I did get head aches and super shits when I first began but by wk2 I notice nothing and feel so great! My tummy looks so much better too, my wifes all jealous as hell n gets mad saying she wont compliment it cuz I use drugs to attain leanness lol Fk it
The rabbits were clinically observed daily at 14:00. The rabbits were placed on a 2-m2 ground area, and gait was individually assessed by direct observation for 20 minutes. The knee and ankle of the intact rabbit limb showed typical flexion and extension cycle during hopping. Lameness was defined as the inability to bear weight and the loss of typical flexion and extension cycle of the affected limb during hopping compared with that of the unaffected limb. The severity of lameness was not quantified. The time taken to return to normal ambulation without lameness of the affected limb was recorded for each group. The lameness period was checked by three independent physiatrists who did not have knowledge of the experimental groups.

OxySelect Pink is an advanced thermogenic and is the only diet pill specifically formulated to enhance the curves of a woman’s body. While other products contain stimulants and huge quantities of dubious fillers and preservatives, OxySelect Pink uses clinically-tested, all-natural extracts designed to help you lose weight. OxySelect Pink is one of the best choices for women looking to get leaner.
Despite the controversies, some scientists continued with additional studies and again proved IGF-1 to actually prolong life…at least in worms.  Then, in 2001, scientists discovered that the use of IGF-1 resulted in a proliferation of cancer cells, especially throughout the breast and colon, and a 2012 study found that both too much or too little IGF-1 could contribute to dying from cancer; implying that IGF-1 actually helped patients with terminal cancer live longer.
Remember the GHRP you select is used for a few reasons. One is to prompt the release of the increase pulse in GH you have initiated with the GHRH you have selected to use. This is by inhibition of Somatostatin. So you are actually selecting the timing of the release of your natural production of  still physiologic amount of GH.  Another reason is to actually contribute a little more to the amplitude of you GH pulse.

You will learn that no single method of using Ipamorelin is right or wrong, and there is more than one route (and dosage cycle length) you can choose, when you do incorporate Ipamorelin into your diet and exercise regimen. Regardless of how high or how long the dosage cycle is, you want to start off on the lower end when you are new to using Ipamorelin, or any growth hormone for that matter. Not only will this reduce the potential risk of experience the side effects, it also ensures your body will ingest the highest levels into the bloodstream. And, it will allow you to gradually increase the dosage and cycle lengths, in order to eventually get to the ideal levels which work best for your body, and for the intended/desired goals you are trying to achieve when using Ipamorelin daily.


If you are interested in using fat loss supplements to assist in your weight loss journey but have never used peptides before, don’t worry, our clinic doctor is available to answer any of your questions. To discuss any concerns, simply email your questions to info@musclepeptides.com.au and our doctor and professional team will get back to you so you can be one step closer to starting your weight loss journey. Want to find out more information right now? Why not see if your questions have already been answered in our FAQs?
The known side effects of IGF-1 injections include jaw pain, facial and hand swelling and heart-rhythm disturbances, especially if doses of more than 100 micrograms (mcg) are injected. Exceeding 100mcg of IGF-1 can actually cause your heart to stop beating and blood pressure to drop dramatically. This is caused by an IGF-1-induced drop in blood phosphate levels, and in the bodybuilding community is often prevented by administering phosphate with the IGF-1.
The particle size of a drug molecule is a crucial factor in the effects of intra-articular injections. The larger the particle size, the longer the drug will stay in a joint, thereby increasing its efficacy [20]. The short residence time of intra-articular AOD9604 when dissolved in saline was due to its rapid uptake by local circulation. However, the combination of AOD9604 with HA may result in more residence time and better effects in the joint. Recent studies [21–23] have shown that the addition of HA to nanoparticles improves the drug effects by increasing drug bioavailability and decreasing systemic absorption after topical administration.
Our Doctor is available for consultations by appointment and can be made by contacting the support team. Our consultation, advice and support is 100% obligation free. All of our Peptides are prescribed by experienced Anti Ageing Doctors. They are then compounded at one of our Australian pharmacies and then shipped Australia wide to Brisbane, Sydney, Melbourne, Hobart, Adelaide, Darwin, Perth and all regional areas.
After the commencement of the active treatment 88.9% of subjects experienced at least one AE, whereby the distribution was similar in the 5 AOD9604 groups and the placebo group. There was a higher incidence (48.4%) of nervous system disorders (mainly headache, 42.6%), gastrointestinal disorders (30.4%, mainly diarrhea unspecified, 9.0%) and infections and infestations (45.3%), than seen before the commencement of active treatment. The distribution of the intensity of AEs was similar across all treatment groups. The percentage of AEs that deemed to be possibly or probably related to the study medication was similar across all treatment groups, including placebo.
In total 118 AEs were reported. No SAEs were reported. The most common adverse event reported by 16/23 subjects (69.6%) was mild or moderate headache. From all the reported AEs three events were reported of severe intensity (one in the 50 µg/kg AOD9604 group, 2 in the placebo group), with one of those events (a feeling of chest tightness) deemed possibly related to the AOD9604 treatment. Mild or moderate euphoria deemed possibly related to treatment, was reported by 5/23 subjects, during the periods when the AOD9604 was administered. There were no reports of euphoria during placebo administration. In total, there was no observable trend between the different treatment groups with respect to the incidence of certain AEs.

After the commencement of active treatment, 78.7% of subjects experienced at least one AE, with the incidence ranging from 75.6% to 83.2% across all treatment groups (83.2% placebo group; 75.6% 0.25 mg AOD9604 group). There was a high incidence of infections and infestations (46.8%, mainly nasopharyngitis, 17.1%), nervous system disorders (30.1%, mainly headache, 25.9%), musculo-skeletal and connective tissue disorders (25.5%, mainly back pain, 8.2%), and gastrointestinal disorders (22.9%, mainly diarrhea, 7.8%). Although the percentage of subjects experiencing AEs in these body systems is higher than in the run-in period there was no obvious pattern with respect to treatment received, suggesting that the increase was likely due to the longer period of assessment in the active treatment phase.
Up to the date of this paper, six clinical trials (three single dose studies and three multiple dose studies from which 2 were long-term studies) have been conducted with AOD9604. In none of the three acute dose-escalating studies (METAOD001 - METAOD003) were there reported any AEs related to the intake of AOD9604, withdrawals from the study caused by AOD9604 or SAEs reported. No treatment related differences were identified upon administration of AOD9604 by IV injection (25 µg - 400 µg/kg bodyweight) or orally (9 mg - 54 mg). Treatment with AOD9604 as a single dosage had no effect on physical examination, vital signs, laboratory parameters, ECG, blood glucose and IGF-1 levels, with results indistinguishable from placebo.
The second long-term study (METAOD006) was a randomized, double-blind, placebo-controlled, multi-center, parallel group study conducted at 16 Australian hospitals and medical centres. In that study 534 were enrolled but of those 502 clinically obese subjects (BMI ≥ 30 kg/m2 and ≤ 45 kg/m2; Median BMI: 36.3 kg/m2, range: 30 to 45.2 kg/m2; 44% males and 56% females) were randomized to receive a daily dose of 0.25, 0.5 or 1mg AOD9604 or placebo for 24 weeks. Prior to this treatment period all subjects underwent a 4-week single-blind placebo run-in period. After cessation of the treatment a 4-week follow-up phase was performed.
Prior to commencement of active treatment, 48.4% of subjects experienced at least one AE. The body system organ classes with the highest incidences of events (> 10%) were the nervous system (17.5%; mainly headache, 14.5%), infections and infestations (15.9%, mainly nasopharyngitis and upper respiratory tract infection, 4.0%), gastrointestinal system (12.4%, mainly diarrhea 3.2%) and musco-skeletal and connective tissue disorders (12.0%, mainly back pain, 4.0%), 32.9% of subjects experienced mild AEs, 38.6% experienced moderate AEs and 36 (7.2%) patients experienced severe AEs. The intensity of AEs was similar across all treatment groups. None of the AEs were deemed to be definitely related to the study treatment.
Improved glucose metabolism after RYGB and sleeve gastrectomy involves several mechanisms: early increased hepatic insulin sensitivity, resulting from reduced liver fat content in response to the postoperative caloric restriction, improved beta-cell function mediated by exaggerated postprandial GLP-1 secretion; as demonstrated by relapse of impaired glucose tolerance in studies blocking the GLP-1 receptor by exendin 9–39, and later after major weight loss increased peripheral insulin sensitivity. Gut hormone secretion changes towards a more anorectic profile and is likely important for less caloric intake and weight loss.

After the commencement of the active treatment 88.9% of subjects experienced at least one AE, whereby the distribution was similar in the 5 AOD9604 groups and the placebo group. There was a higher incidence (48.4%) of nervous system disorders (mainly headache, 42.6%), gastrointestinal disorders (30.4%, mainly diarrhea unspecified, 9.0%) and infections and infestations (45.3%), than seen before the commencement of active treatment. The distribution of the intensity of AEs was similar across all treatment groups. The percentage of AEs that deemed to be possibly or probably related to the study medication was similar across all treatment groups, including placebo.
However, using a credit card, Crikey was able to easily order a 5 milligram vial of GHRP-6 without a permit or a prescription from the US-based Peptide Labs for the the bargain-basement price of $US18.50 plus $US10 postage and handling. A disclaimer attached to the sale stresses the peptide is "not for human use" and is for "LABORATORY USE ONLY". At 99% purity, the peptide boasts "paramount attributes for experiments involving muscle synthesis and recovery". Delivery is promised between 7-14 days after the payment is processed.
×